Zomedica报告第四季度业绩

Gross margin was 70.3% for the fourth quarter of 2024.

Net Loss for the three months ended December 31, 2024, was $7.2 million, compared to net loss of $22.4 million in the fourth quarter of 2023.

**Adjusted non-GAAP EBITDA loss (which includes adjustments for non-cash stock compensation and non-cash impairment charges) for the three months ended December 31, 2024, was $5.4 million, compared to $6.7 million in the fourth quarter of 2023.

Total cash used during the quarter was approximately $6.5 million. When adjusted for non-recurring one-time items, non-GAAP operating cash burn was approximately $4.2 million.